FDA Approves Tymlos as a Treatment to Increase Bone Density in Men with
Osteoporosis at High Risk for Fracture

December 20, 2022 – Radius Health, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos (abaloparatide), a parathyroid hormone related peptide [PTHrP(1-34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.

Tymlos is a man-made form of parathyroid hormone that exists naturally in the body.

Read more…